DSM Nutritional Products, 4303 Kaiseraugst, Switzerland.
Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Nutrients. 2018 Jun 15;10(6):775. doi: 10.3390/nu10060775.
Decreases in global cardiovascular disease (CVD) mortality and morbidity in recent decades can be partly attributed to cholesterol reduction through statin use. -3 long chain polyunsaturated fatty acids are recommended by some authorities for primary and secondary CVD prevention, and for triglyceride reduction. The residual risk of CVD that remains after statin therapy may potentially be reduced by -3 long chain polyunsaturated fatty acids. However, the effects of concomitant use of statins and -3 long chain polyunsaturated fatty acids are not well understood. Pleiotropic effects of statins and -3 long chain polyunsaturated fatty acids overlap. For example, cytochrome P450 enzymes that metabolize statins may affect -3 long chain polyunsaturated fatty acid metabolism and vice versa. Clinical and mechanistic study results show both synergistic and antagonistic effects of statins and -3 long chain polyunsaturated fatty acids when used in combination.
近几十年来，全球心血管疾病 (CVD) 死亡率和发病率的下降部分归因于通过使用他汀类药物降低胆固醇。一些权威机构建议将长链多不饱和脂肪酸用于一级和二级 CVD 预防以及降低甘油三酯。他汀类药物治疗后仍存在的 CVD 残余风险可能会通过长链多不饱和脂肪酸降低。然而，他汀类药物和长链多不饱和脂肪酸同时使用的效果尚不清楚。他汀类药物和长链多不饱和脂肪酸的多效性作用重叠。例如，代谢他汀类药物的细胞色素 P450 酶可能会影响长链多不饱和脂肪酸的代谢，反之亦然。临床和机制研究结果表明，他汀类药物和长链多不饱和脂肪酸联合使用时具有协同和拮抗作用。
